Cognitive dysfunction associates with white matter hyperintensities and subcortical atrophy on magnetic resonance imaging of the elderly diabetes mellitus Japanese elderly diabetes intervention trial (J-EDIT)

Diabetes/Metabolism Research and Reviews

Volumn 22, Issue 5, 2006, Pages 376-384

  Akisaki, Taichi ^a   Sakurai, Takashi ^a   Takata, Toshihiro ^a   Umegaki, Hiroyuki ^b   Araki, Atsushi ^c   Mizuno, Sachiko ^d   Tanaka, Shiro ^d   Ohashi, Yasuo ^d   Iguchi, Akihisa ^b   Yokono, Koichi ^a   Ito, Hideki ^e  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c Tokyo Metropolitan Institute of Gerontology   (Japan)

^d UNIVERSITY OF TOKYO   (Japan)

^e Tokyo Metropolitan Health and Medical Treatment Corporation   (Japan)

Author keywords

Cognitive dysfunction; Elderly; Periventricular hyperintensity; Subcortical atrophy; Type 2 diabetes mellitus; White matter hyperintensities

Indexed keywords

GLUCOSE; INSULIN;

AGED; ARTICLE; BASAL GANGLION; BLOOD GLUCOSE MONITORING; BLOOD PRESSURE; BRAIN ATROPHY; CLINICAL FEATURE; COGNITIVE DEFECT; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; ELDERLY CARE; FEMALE; HUMAN; INFORMATION PROCESSING; INSULIN TREATMENT; JAPAN; LATERAL BRAIN VENTRICLE; LIPID METABOLISM; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; NEUROPSYCHOLOGICAL TEST; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE IMAGING; PARIETAL LOBE; PREDICTION; PRIORITY JOURNAL; REGRESSION ANALYSIS; THALAMUS; VERBAL MEMORY; WHITE MATTER;

AGED; ATROPHY; BODY MASS INDEX; BRAIN; COGNITION DISORDERS; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INFORMED CONSENT; JAPAN; MAGNETIC RESONANCE IMAGING; MALE; SOCIOECONOMIC FACTORS;

EID: 33749001980     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.632     Document Type: Article

References (68)

1. Kawamori R. Diabetes trends in Japan. Diabetes Metab Res Rev 2002; 18: S9-S13.
2. Davidson JA. Treatment of the patient with diabetes: importance of maintaining target HbA(1c). Curr Med Res Opin 2004; 20: 1919-1927.
3. Miles WR, Root HF. Psychologic tests applied to diabetic patients. Arch Intern Med 1922; 30: 767-777.
4. Strachan MW, Ewing FM, Deary IJ, et al. Is type 2 diabetes associated with an increased risk of cognitive dysfunction? A critical review of published studies. Diabetes Care 1997; 20: 438-445.
5. Ott A, Stolk RP, van Harskamp F, et al. Diabetes mellitus and the risk of dementia: the Rotterdam study. Neurology 1999; 53: 1937-1942.
6. Luchsinger JA, Tang MX, Stern Y, et al. Diabetes mellitus and risk of Alzheimer's disease and dementia with stroke in a multiethnic cohort. Am J Epidemiol 2001; 154: 635-641.
7. Peila R, Rodriguez BL, Launer LJ. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia aging study. Diabetes 2002; 51: 1256-1262.
8. MacKnight C, Rockwood K, Awalt E, et al. Diabetes mellitus and the risk of dementia, Alzheimer's disease and vascular cognitive impairment in the Canadian study of health and aging. Dement Geriatr Cogn Disord 2002; 14: 77-83.
9. Arvanitakis Z, Wilson RS, Bienias JL, et al. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 2004; 61: 661-666.
10. Gispen WH, Biessels GJ. Cognition and synaptic plasticity in diabetes mellitus. Trends Neurosci 2000; 23: 542-549.
11. Watson GS, Craft S. Modulation of memory by insulin and glucose: neuropsychological observation in Alzheimer's disease. Eur J Pharmacol 2004; 490: 97-113.
12. Buckner RL. Memory and executive function in aging and AD: multiple factors that cause decline and reserve factors that compensate. Neuron 2004; 44: 195-208.
13. Lazarus R, Prettyman R, Cherryman G. White matter lesions on magnetic resonance imaging and their relationship with vascular risk factors in memory clinic attenders. Int J Geriatr Psychiatry 2005; 20: 274-279.
14. The Expert Committee On the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003; 26(suppl. 1): 5-20.
15. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. (4th edn). American Psychiatric Association: Washington, DC, 1994.
16. Amiel SA. In Iatrogenic Hypoglycemia, Kahn CR, Weir GC, King GL, Jacobson AM, Moses AC, Smith RJ (eds). Lippincott Williams & Wilkins: Boston, MA, 2005; 671-686.
17. Piguet O, Ridley LJ, Grayson DA, et al. Comparison white matter lesions on T2 and FLAIR MRI in the Sydney older persons study. Eur J Neurol 2005; 12: 399-402.
18. de Groot JC, de Leeuw F-E, Oudkerk M, et al. Cerebral white matter lesions and cognitive function: the Rotterdam scan study. Ann Neurol 2000; 47: 145-151.
19. Erkinjuntti T, Inzitari D, Pantoni L, et al. Research criteria for subcortical vascular dementia in clinical trials. J Neural Transm Suppl 2000; 59: 23-30.
20. Evans WA. An encephalographic ratio for estimating ventricular enlargement and cerebral atrophy. Arch Neurol Psychiatry 1942; 47: 931.
21. Haug G. Age and sex dependence of the size of normal ventricles on computed tomography. Neuroradiology 1977; 14: 201.
22. Sawai F. Computed tomographical diagnosis of brain atrophy by aging. J Nara Med Assoc 1987; 38: 974-979.
23. Ushida C, Umegaki H, Hattori A, et al. Assessment of brain atrophy in elderly subjects with diabetes mellitus by computed tomography. Geriatr Gerontol Int 2001; 1: 33-37.
24. Stroop JR. Studies of interference in serial verbal reactions. J. Exp. Psychol. 1935; 18: 643-662.
25. Wechsler D. Manual for the Wechsler Adult Intelligence Scale-Revised. Psychological Corporation: New York, 1981.
26. Mohs RC, Rosen WG, Davis KL. The Alzheimer's disease assessment scale; an instrument for assessing treatment efficacy. Psychopharmacol Bull 1983; 19: 448-450.
27. Ueda M, Takayama Y, Sasanuma S. Memory disorders in the elderly stage of dementia of the Alzheimer type: preliminary findings. Jpn J Neuropsychology 1996; 12: 178-186.
28. Folstein MF, Folstein SE, McHugh PR. 'Mini-mental state.' A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-198.
29. Johnson RA, Wichern DW. Applied Multivariate Statistical Analysis, (5th ed). Prentice Hall: London. 2002.
30. Razavi AR, Gill H, Stal O, et al. Exploring cancer register data to find risk factors for recurrence of breast cancer - application of canonical correlation analysis. BMC Med Inform Decis Mak 2005; 22: 5-29.
31. Sherry A, Henson RK. Conducting and interpreting canonical correlation analysis in personality research: a user-friendly primer. J Pers Assess 2005; 84: 37-48.
32. O'Brien JT, Wiseman R, Burton EJ, et al. Cognitive associations of subcortical white matter lesions in older people. Ann N Y Acad Sci 2002; 977: 436-444.
33. de Leeuw FE, de Groot JC, Oudkerk M, et al. Hypertension and cerebral white matter lesions in prospective cohort study. Brain 2002; 125: 765-772.
34. Ylikoski R, Ylikoski A, Erkinjuntti T, et al. White matter changes in healthy elderly persons correlates with attention and speed of mental processing. Arch Neurol 1993; 50: 818-824.
35. Schmidt R, Fazekas F, Offenbacher H, et al. Neuropsychologic correlates of MRI white matter hyperintensities: a study of 150 normal volunteers. Neurology 1993; 43: 2490-2494.
36. Ylikoski R, Erkinjuntti T, Raininko R, et al. White matter hyperintensities on MRI in the neurological nondiseased elderly. Analysis of cohorts of consecutive subjects aged 55 to 85 years living at home. Stroke 1995, 26: 1171-1177.
37. Gunning-Dixon FM, Raz N. The cognitive correlates of white matter abnormalities in normal aging: A quantitative review. Neuropsychology 2000; 14: 224-232.
38. de Groot JC, de Leeuw FE, Oudkerk M, et al. Periventricular cerebral white matter lesions predict rate of cognitive decline. Ann Neurol 2002; 52: 335-341.
39. Filley CM. The behavioral neurology of cerebral white matter. Neurology 1998; 50: 1535-1540.
40. Schmahmann JD. Vascular syndromes of the thalamus. Stroke 2003; 34: 2264-2278.
41. Rapoport SI. Integrated phylogeny of the primate brain, with special reference to humans and their disease. Brain Res Brain Res Rev 1990; 15: 267-294.
42. Salmon E, Sadzot B, Maquet P, et al. Differential diagnosis of Alzheimer's disease with PET. J Nucl Med 1994; 35: 391-398.
43. Fazekas F, Kleinert R, Offenbacher H, et al. Pathologic correlates of incidental MRI white matter signal hyperintensities. Neurology 1993; 43: 1683-1689.
44. Udaka F, Sawada H, Kameyama M. White matter lesions and dementia MRI-pathological correlation. Ann N Y Acad Sci 2002; 977: 411-415.
45. Pugh KG, Lipsitz LA. The microvascular frontal-subcortical syndrome of aging. Neurobiol Aging 2002; 23: 421-431.
46. Longstreth WT, Manolio TA, Arnold A, et al. The Cardiovascular Health Study. Clinical correlates of white matter findings on cranial magnetic resonance imaging of 3301 elderly people. Stroke 1996; 27: 1274-1282.
47. Raz N, Rodrigue KM, Acker JD. Hypertension and the brain: vulnerability of the prefrontal regions and executive functions. Behav Neurosci 2003; 117: 1169-1180.
48. Taylor WD, MacFall JR, Provenzale JM, et al. Serial MR imaging of volumes of hyperintense white matter lesions in elderly patients: correlation with vascular risk factors. AJR Am J Roentgenol 2003; 181: 571-576.
49. Cosway R, Strachan MWJ, Dougall A, et al. Cognitive function and infonnation processing in type 2 diabetes. Diabet Med 2001; 18: 803-810.
50. Mogi N, Umegaki H, Hattori A, et al. Cognitive function in Japanese elderly with type 2 diabetes mellitus. J Diabetes Complications 2004; 18: 42-46.
51. Cox DJ, Kovatchev BP, Gonder-Frederick LA, et al. Relationships between hyperglycemia and cognitive performance among adults with type 1 and type 2 diabetes. Diabetes Care 2005; 28: 71-77.
52. den Heijer T, Vermeer SE, van Dijk EJ, et al. Type 2 diabetes and atrophy of medial temporal lobe structures on brain MRI. Diabetologia 2003; 46: 1604-1610.
53. Ceriello A, Quatraro A, Guigliano D. Diabetes mellitus and hypertension: the possible role of hyperglycemia through oxidative stress. Diabetologia 1993; 36: 265-266.
54. Lipinski B. Pathophysiology of oxidative stress in diabetes mellitus. J Diabetes Complications 2001; 15: 203-210.
55. Lander HM, Tauras JM, Ogiste JS, et al. Activation of the receptor for advanced glycation end products triggers a p21 (ras) -dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J Biol Chem 1997; 272: 17810-17814.
56. Girones X, Guimera A, Cruz-Sanchez CZ, et al. N epsiloncarboxymethyllysine in brain aging, diabetes mellitus, and Alzheimer's disease. Free Radic Biol Med 2004; 36: 1241-1247.
57. Yan SD, Chen X, Fu J, et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 1996; 382: 685-691.
58. Thomas T, Thomas G, McLendon C, et al. β-Amyloid-mediated vasoactivity and vascular endothelial damage. Nature 1996; 380: 168-171.
59. Sastre J, Pallardo FV, Vina J. Mitochondrial oxidative stress plays a key role in aging and apoptosis. IUBMB Life 2000; 49: 427-435.
60. Petitti DB, Bhatt H. Retinopathy as a risk factor for nonembolic stroke in diabetic subjects. Stroke 1995; 26: 593-596.
61. Inoue T, Fushimi H, Yamada Y, et al. Asymptomatic multiple lacunae in diabetics and non-diabetics detected by brain magnetic resonance imaging. Diabetes Res Clin Pract 1996; 31: 81-86.
62. Frisoni GB, Scheltens PH, Galluzzi S, et al. Neuroimaging tools to rate regional atrophy, subcortical cerebrovascular disease, and regional cerebral blood flow and metabolism: consensus paper of the EADC. J Neurol Neurosurg Psychiatry 2003; 74: 1371-1381.
63. Insel KC, Palmer RF, Stroup-Benham CA, et al. Association between change in systolic blood pressure and cognitive decline among elderly Mexican Americans: data from the Hispanic established population for epidemiology study of the elderly. Exp Aging Res 2005; 31: 35-54.
64. den Heijer T, Launer LJ, Prins ND, et al. Association between blood pressure, white matter lesions, and atrophy of the medial temporal lobe. Neurology 2005; 64: 263-267.
65. Forette F, Seux ML, Staessen JA, et al. Prevention of dementia in randomized double-blind placebo-controlled systolic hypertension in Europe (Syst-Eur) trial. Lancet 1998; 352: 1347-1351.
66. Jick H, Zornberg GL, Jick SS, et al. Statins and the risk of dementia. Lancet 2000; 356: 1627-1631.
67. Kristine Y, Elizabeth BC, Feng L, et al. Serum lipoprotein levels, stain use, and cognitive function in older women. Arch Neurol 2002; 59: 378-384.
68. Shepherd J. A prospective study of pravastatin in the elderly at risk: New hope for older persons. Am J Geriatr Cardiol 2004; 13: 17-24.